Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.40 |
| ▸ | F10 | P00742 | 4/20 | 0.40 |
| ▸ | KLK1 | P06870 | 4/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 3/20 | 0.37 |
| ▸ | PLAU | P00749 | 3/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450440 | 0.93 | KLK1 (0.38) | F2F10KLK1KLK5ITGB3 | |
| SCHEMBL6462435 | 0.90 | ITGB3 (0.43) | F2F10KLK1KLK5ITGB3 | |
| SCHEMBL6455724 | 0.85 | F2 (0.39) | F2F10KLK1KLK5F9 | |
| SCHEMBL6457229 | 0.82 | F2 (0.41) | F2F10KLK1KLK5ITGB3 | |
| SCHEMBL6451890 | 0.75 | F2 (0.60) | F2F10KLK1KLK5F9 | |
| SCHEMBL7450241 | 0.75 | F2 (0.57) | F2F10KLK1KLK5ITGB3 | |
| SCHEMBL7453719 | 0.72 | F2 (0.42) | F2F10KLK1KLK5ITGB3 | |
| SCHEMBL7442317 | 0.72 | F2 (0.54) | F2F10KLK1KLK5ITGB3 | |
| SCHEMBL7424427 | 0.69 | F2 (0.42) | F2F10KLK1KLK5F9 | |
| SCHEMBL7422210 | 0.67 | F2 (0.40) | F2F10KLK1KLK5ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517687-A1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-30 | — | — | EP | claimed |
| WO-2004000310-A1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-31 | — | — | WO | claimed |
| EP-1517687-A1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000310-A1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-31 | — | — | WO | disclosed |